Long-term survival and cause-specific mortality of patients newly diagnosed with tuberculosis in São Paulo state, Brazil, 2010–15: a population-based, longitudinal study. by Ranzani, Otavio T et al.
www.thelancet.com/infection   Vol 20   January 2020 123
Articles
Lancet Infect Dis 2020; 
20: 123–32
Published Online 
October 29, 2019 
https://doi.org/10.1016/ 
S1473-3099(19)30518-3
See Comment page 11
Pulmonary Division, Heart 
Institute (InCor), Hospital das 
Clinicas (HCFMUSP), Faculdade 
de Medicina da Universidade 
de São Paulo, São Paulo, Brazil 
(O T Ranzani PhD, 
Prof C R R Carvalho PhD); 
London School of Hygiene & 
Tropical Medicine, London, UK 
(O T Ranzani, 
Prof L C Rodrigues PhD); 
São Paulo Tuberculosis 
Program, Epidemiological 
Surveillance Centre 
“Prof Alexandre Vranjac” 
(S Bombarda PhD) and Centro 
de Informações em Vigilância 
em Saúde (CIVS), 
Coordenadoria de Controle de 
Doenças (C M Minto MSc), 
São Paulo Secretary of Health, 
São Paulo, Brazil; and 
Department of Epidemiology, 
Faculty of Public Health, 
University of São Paulo, 
São Paulo, Brazil 
(Prof E A Waldman PhD)
Correspondence to: 
Dr Otavio T Ranzani, Pulmonary 
Division, Faculdade de Medicina 
da Universidade de São Paulo, 
CEP 01246903, São Paulo, Brazil 
otavioranzani@usp.br
Long-term survival and cause-specific mortality of patients 
newly diagnosed with tuberculosis in São Paulo state, Brazil, 
2010–15: a population-based, longitudinal study
Otavio T Ranzani, Laura C Rodrigues, Sidney Bombarda, Cátia M Minto, Eliseu A Waldman, Carlos R R Carvalho
Summary
Background Long-term survival and cause-specific mortality of patients who start tuberculosis treatment is rarely 
described. We aimed to assess the long-term survival of these patients and evaluate the association between vulnerable 
conditions (social, health behaviours, and comorbidities) and cause-specific mortality in a country with a high burden 
of tuberculosis.
Methods In this population-based, longitudinal study in São Paulo state, Brazil, we described the 5-year survival of 
patients who were newly diagnosed with tuberculosis in 2010. We included patients with newly-diagnosed tuberculosis, 
aged 15 years or older, and notified to the São Paulo State Tuberculosis Program in 2010. We excluded patients whose 
diagnosis had changed during follow-up (ie, they did not have tuberculosis) and patients who had multidrug-resistant 
(MDR) tuberculosis. We selected our population with tuberculosis from the dedicated electronic system TBweb. Our 
primary objective was to estimate the excess mortality over 5 years and within the group who survived the first year, 
compared with the general São Paulo state population. We also estimated the association between social vulnerability 
(imprisonment and homelessness), health behaviours (alcohol and drug use), and comorbidities (diabetes and mental 
disorders) with all-cause and cause-specific mortality. We used the competing risk analysis framework, estimating 
cause-specific hazard ratios (HRs) adjusted for potential confounding factors.
Findings In 2010, there were 19 252 notifications of tuberculosis cases. We excluded 550 cases as patients were younger 
than 15 years, 556 cases that were not tuberculosis, 2597 retreatments, and 48 cases of MDR tuberculosis, resulting in 
a final cohort of 15 501 patients with tuberculosis. Over a period of 5 years from tuberculosis diagnosis, 2660 (17%) of 
15 501 patients died. Compared with the source population, matched by age, sex, and calendar year, the standardised 
mortality ratio was 6·47 (95% CI 6·22–6·73) over 5 years and 3·93 (3·71–4·17) among those who survived the first 
year. 1197 (45%) of 2660 deaths were due to infection. Homelessness and alcohol and drug use were associated with 
death from infection (adjusted cause-specific HR 1·60, 95% CI 1·39–1·85), cardiovascular (1·43, 1·06–1·95), and 
external or ill-defined causes of death (1·80, 1·37–2·36). Diabetes was associated with deaths from cardiovascular 
causes (1·70, 1·23–2·35).
Interpretation Patients newly diagnosed with tuberculosis were at a higher risk of death than were the source 
population, even after tuberculosis treatment. Post-tuberculosis sequelae and vulnerability are associated with excess 
mortality and must be addressed to mitigate the tuberculosis burden worldwide.
Funding Wellcome Trust.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Tuberculosis is an ancient disease that still causes a 
considerable number of deaths worldwide, and is among 
the leading preventable causes of death yet to be eliminated.1 
Vulnerability—when individuals are susceptible to 
physical, biological, psychological, and socioeconomic 
stressors and have few resources to cope with these2—is 
the main determinant of tuberculosis epidemics and 
treatment outcomes3 and is considered a fundamental 
target that must be addressed to mitigate the tuberculosis 
burden worldwide.1,4
Most studies have described the survival of patients 
with tuberculosis while they received treatment or shortly 
after treatment completion.3 To our knowledge, there are 
few studies concerning long-term tuberculosis survival 
(ie, 5 years after diagnosis),5–8 and this knowledge is even 
scarcer in low-income and middle-income countries.3,9–11 
Moreover, detailed evaluation of causes of death in 
cohorts with tuberculosis has not received much 
attention12 and there is a paucity of population-based 
studies that are not focused on tuberculosis and HIV 
coinfection. Evaluation of survival after tuberculosis 
treatment and associated causes of death allows 
quantification of the post-tuberculosis mortality burden 
and can be useful for planning preventive measures to 
mitigate post-tuberculosis sequelae.11,13
We aimed to describe 5-year survival and causes of 
death of patients with tuberculosis in a population-based 
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longitudinal study in São Paulo state, Brazil. We hypo-
thesised that patients with tuberculosis would have lower 
survival compared with the source population, and that 
vulnerable conditions would be associated with this 
excess mortality and cause-specific mortality.
Methods
Study design and participants
We did a retrospective, longitudinal study with data from 
the São Paulo State Tuberculosis Program, Brazil. 
São Paulo state is divided into 645 municipalities and 
the national public health system covers tuberculosis 
diagnosis and treatment free of charge. São Paulo state had 
a tuberculosis incidence of 39·1 per 100 000 inhabitants in 
2010, and the highest absolute number of tuberculosis 
cases in Brazil.14,15
We had official written permission for use of the data 
from the data guardian (the Health Department of 
São Paulo state) and ethics approval from the local ethics 
committee (protocol 270/14). The data for the general 
population is publicly available and did not require ethics 
approval.
We included patients with newly-diagnosed tuber culosis, 
aged 15 years or older, and notified to the São Paulo 
State Tuberculosis Program in 2010. We defined newly 
diagnosed as those who had never been treated for 
tuberculosis or who had taken anti-tuberculosis drugs for 
1 month or less.16 We excluded patients whose diagnosis 
had changed during the follow-up period (ie, they did not 
have tuberculosis) and patients who had multidrug-
resistant (MDR) tuberculosis.16 Patients without antibiotic 
susceptibility testing were assumed to not have MDR 
tuberculosis, considering the low prevalence of MDR 
disease in São Paulo state (<1%).1,17 The source population 
(São Paulo state) comprised 41 million inhabitants (around 
22% of the Brazilian population), most of whom lived in 
urban areas with marked indexes of inequality and poverty 
in 2010 (appendix p 3).14
Procedures
All data sources used in this study are described in 
the appendix (p 4). We selected the population with 
tuberculosis from the dedicated electronic system 
TBweb.14,18 This dedicated platform includes all notified 
cases of bacteriologically confirmed or clinically diagnosed 
tuberculosis, as defined by WHO,16 from residents in 
São Paulo state. Tuberculosis notification is compulsory in 
Brazil and only notified cases can start treatment. TBweb 
receives continuous input regarding patient treatment 
status from health-care units responsible for patient care 
until the end of treatment.14 We included patients from 
Jan 1, 2010, to Dec 31, 2010 (dates of notification). Detailed 
descriptions of definitions and recoding for variables from 
TBweb are given in the appendix (pp 5–6).
We evaluated the long-term survival and causes of 
death from the Mortality Information System (SIM) 
located at the Health Department of São Paulo state,19 
which contains causes of death for all residents (including 
deaths occurring inside and outside São Paulo state). 
Death certificates from SIM are carefully revised for 
standardisation and appropriate definitions, following 
WHO recommendations and using the ICD-10.20 We did 
Research in context
Evidence before this study
We searched PubMed for studies that assessed long-term 
cause-specific mortality for tuberculosis in adults and were 
published in English, Spanish, or Portuguese, from PubMed’s 
inception until June 30, 2018, with the following terms 
(“tuberculosis” OR “TB”) AND (“cause-specific mortality” OR 
“cause of death” OR “CoD”). Few studies evaluated long-term 
survival of newly-diagnosed patients. Most studies focused on 
short-term survival, and those that did look at long-term 
survival were mainly done in high-income countries. 
These studies described higher mortality in patients with 
tuberculosis compared with source populations or household 
controls. We found no detailed evaluations of cause-specific 
mortality nor any studies that evaluated the association 
between vulnerable conditions and cause-specific mortality 
with a competing risk framework for causes of death.
Added value of this study
In a middle-income country, we showed that the rate of death 
among patients with tuberculosis was six-times higher than the 
source population. This excess mortality was also observed among 
those who survived the first year of follow-up and was higher in 
patients with at least one vulnerable condition (eg, imprisonment, 
homelessness, alcohol and drug use, and diabetes). Infection was 
responsible for 45% of deaths. Homelessness, alcohol and drug 
use, and diabetes were associated with all-cause mortality. We 
have added to the literature showing that vulnerable conditions 
are associated with cause-specific mortality; homelessness and 
alcohol and drug use were associated with death from infection, 
respiratory, cardiovascular, and external or ill-defined causes, while 
diabetes was associated with deaths from cardiovascular causes.
Implications of all the available evidence
We showed the value of long-term follow-up of patients with 
tuberculosis, providing data to support a better understanding 
of tuberculosis burden, particularly after treatment. Vulnerable 
conditions are the main determinants of tuberculosis epidemics 
and treatment outcomes, and we observed that they are 
associated with cause-specific mortality. Two direct implications 
from our study are that mortality surveillance systems for 
long-term follow-up are needed and preventive measures for 
patients with vulnerable conditions should be reinforced. 
These measures could include reinforcing pneumococcal and 
influenza vaccination uptake, intensifying cardiovascular event 
prevention, a programme to reduce alcohol consumption, and 
tackling devastating conditions, such as homelessness.
See Online for appendix
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a probabilistic record linkage followed by manual 
revision between the tuberculosis cohort and mortality 
database (appendix p 7).
We used the WHO ICD-10 hierarchy and standard 
grouping of causes of death.20 Our primary analysis used 
causes of death as defined by WHO chapters; we selected 
six causes of death as competing events of interest—
infection, respiratory, neoplasia, cardiovascular, external 
causes, and ill-defined. We did two sensitivity analyses, 
regrouping the causes of death into five new groups, to 
be more specific and infor mative about tuberculosis 
and vulnerable conditions (tuberculosis, infections 
not related to tuberculosis, respiratory causes without 
infection, ischaemic heart or cerebrovascular disease, 
and external causes or ill-defined) and regrouping causes 
of death into two groups to explore the associated burden 
of tuberculosis (tuberculosis as the underlying cause of 
death and any mention of tuberculosis codes in other 
lines). These divisions were defined a priori during the 
design of this study. Further information and the exact 
codes used are shown in the appendix (p 8).
Using a theoretical model about vulnerability and 
tuberculosis (appendix p 9), we selected six exposures 
present in the tuberculosis literature as different 
constructs of vulnerability,1,3,4,14 labelling them social 
vulnerability (homeless or prison inmates), health 
behaviours (alcohol and drug use), and comorbidities 
(biological vulnerability), with diabetes and mental 
illness.3,21 We also combined homelessness and alcohol 
and drug use as they are frequently associated,14 
generating two derived variables as follows: a binary 
variable representing the presence of at least of one these 
conditions and another variable with four levels adding 
each vulnerability (appendix p 5).
Outcomes
Our primary objective was to estimate excess mortality 
over 5 years and within the group who survived the 
first year, compared with the source population. Our 
secondary objective was to estimate the excess mortality 
in patients with tuberculosis with vulnerable conditions 
(social vulnerability, health behaviours, and comor-
bidities). Finally, we estimated the association between 
patients’ vulnerable conditions and all-cause and cause-
specific mortality.
Statistical analysis
We chose to run our study for 1 year because of the 
feasibililty of doing a probabalistic record linkage, 
allowing for manual review of all possible pairs and 
increasing sensitivity and specificity to ascertain long-
term survival. Therefore, the sample size was pragmatic. 
We were aware of the yearly sample size of newly 
diagnosed patients and their short-term survival and, for 
most of the exposures of interest, the cohort sample size 
and number of events were greater than that requested 
for typical power (80%) and α errors (5%). Continuous 
variables are listed as mean (SD) and median (IQR), as 
appropriate. Counts are described as proportions.
We described all-cause 5-year survival and compared 
this with the expected survival of the underlying 
population (ie, São Paulo state population) and estimated 
standardised mortality ratios (SMR).22,23 We calculated 
expected survival and mortality from lifetables for the 
São Paulo state population, obtained from the Brazilian 
Institute of Geography and Statistics, matched by age (by 
1 year age bands), sex (male vs female), and calendar year 
(2010, 2011, 2012, 2013, 2014, and 2015). We estimated 
SMR for the whole population and among those with or 
without any of the six exposures of interest, over 5 years 
and after 1 year of starting tuberculosis treatment.
We evaluated the association between the six exposures 
and all-cause survival among the tuberculosis cohort using 
Cox proportional hazards models. We analysed all-cause 
survival over 5 years and split this into early (all-cause 
survival over the first year) and late (all-cause survival after 
the first year) categories. In a sensitivity analysis for the 
late models, we ran a Cox model starting at the date of 
treatment outcome. We used previous knowledge to build 
a directed acyclic graph and select potential confounding 
factors a priori (appendix p 10), then estimated the crude 
and age-adjusted and sex-adjusted association for each 
exposure. We fit a fully adjusted model, entering the 
six exposures concurrently and adjusting for potential 
confounders (age, sex, level of education, self-reported skin 
colour, immunosuppression from causes other than HIV 
infection, anatomical tuberculosis classification, and 
microbiological status). We adjusted for HIV status and 
place of diagnosis by stratification in the fully adjusted 
model, allowing for different baseline hazard rates between 
strata. We tested the proportional hazard assumption, 
assessing interactions with survival time and examining 
Schoenfeld residual plots. Diabetes had non-proportional 
hazards and we accommodated for this by allowing time-
dependent effects with an interaction term with survival 
time. In a post-hoc analysis, we modelled for diabetes in 
the fully adjusted model with flexible parametric survival 
modelling. For the Cox models, the time axis was follow-
up and patients were right censored, with the time of end 
of follow-up fixed as Aug 31, 2015 (appendix p 7).
We analysed cause-specific mortality with competing 
risk analysis, as a death from a cardiovascular cause 
precluded the occurrence of other causes of death. We 
illustrated the occurrence of different causes of death 
over time and derived cumulative incidence function 
curves. The association between exposure and cause-
specific mortality was estimated by cause-specific hazard 
ratios (HRs).24 We fit the same fully adjusted model as for 
all-cause mortality and considered each cause of death as 
competing events.
We had missing values for five covariates and self-
reported skin colour and education had around 20% 
missing values. We investigated the missingness pattern 
and did multiple imputation, generating ten imputed 
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datasets, by fully conditional specification, allowing for 
non-linearity of the Cox model. We ran a sensitivity 
analysis of all-cause survival in the complete case dataset. 
A description of the multiple imputation is shown in the 
appendix (p 11). A description of our sensitivity analyses 
is shown in the appendix (p 12).
All analyses were done with Stata version 13.1. 
We followed STROBE guideline recommendations.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had full access to all data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
In 2010, there were 19 252 notifications of tuberculosis 
cases. We excluded 550 cases as patients were younger 
than 15 years, 556 cases that were not tuberculosis, 
2597 retreatments, and 48 cases of MDR tuberculosis, 
resulting in a final cohort of 15 501 patients with 
tuberculosis. We recorded baseline characteristics of the 
15 501 patients with tuberculosis and demographic 
characteristics of the São Paulo state population (table 1). 




São Paulo state 
population 2010*
Age, years†
15–25 2930 (19%) 21%
>25–35 4055 (26%) 23%
>35–45 3247 (21%) 19%
>45–55 2605 (17%) 16%
>55–65 1527 (10%) 11%
>65 1118 (7%) 10%
Sex
Female 4683 (30%) 52%
Male 10 818 (70%) 48%
Self-reported skin colour‡
White 7129 (55%) 64%
Brown or mixed 3989 (31%) 29%
Black 1488 (12%) 6%
Asian or Indigenous 237 (2%) 1%
Years of schooling§
Illiterate 521 (4%) 4%
1–3 1465 (12%) ··
4–7 4620 (38%) ··
8–11 4518 (37%) ··
12–14 798 (6%) 23%
≥15 379 (3%) 41%
Incarcerated
Yes 1609 (10%) <1%
No 13 892 (90%) >99%
Homeless
Yes 391 (3%) ··
No 15 110 (97%) ··
Alcohol use
Yes 2053 (13%) ··
No 13 448 (87%) ··
Drug use
Yes 1019 (7%) ··
No 14 482 (93%) ··
Diabetes
Yes 880 (6%) 13%
No 14 621 (94%) ··
Mental disorder
Yes 336 (2%) ··
No 15 165 (98%) ··
HIV status
Negative 11 155 (72%) ··
Positive 1874 (12%) <1%
Unknown 2472 (16%) ··
Immunosuppression from causes other than HIV infection
Yes 113 (1%) ··
No 15 388 (99%) ··
(Table 1 continues in next column)
Entire cohort 
(n=15 501)
São Paulo state 
population 2010*
(Continued from previous column)
Anatomical classification
Pulmonary tuberculosis 12 458 (80%) ··
Pulmonary tuberculosis and 
extrapulmonary tuberculosis
409 (3%) ··
Extrapulmonary tuberculosis 2280 (15%) ··
Miliary or disseminated 354 (2%) ··
Microbiological status¶
Positive 10 956 (78%) ··
Negative 3010 (22%) ··
Place of diagnosis||
Primary or outpatient care 9349 (61%) ··
Emergency or urgent care 
facility
3300 (22%) ··
Hospitalised 2465 (16%) ··
Upon autopsy 159 (1%) ··
Treatment outcome
Treatment success 12 227 (79%) ··
Treatment failure 254 (2%) ··
Death 1247 (8%) ··
Loss to follow-up 1537 (10%) ··
Not evaluated 236 (2%) ··
*Data sources (appendix p 4) were the 2010 census (age, sex, education, 
and self-reported skin colour), the primary care database (diabetes), 
InfoPen (incarceration), and Notifiable Diseases Information System (HIV status). 
We did not find a population-based estimate for some variables and we could 
not redistribute the data for education from the 2010 census on all category levels 
present in the tuberculosis data. †Missing data n=19 (<1%). ‡Missing data 
n=2658 (17%). §Missing data n=3200 (21%). ¶Missing data n=1535 (10%). 
||Missing data n=228 (2%).
Table 1: Baseline characteristics
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Over a period of 5 years from tuberculosis diagnosis, 
2660 (17%) of 15 501 patients died. Among 15 342 patients 
who started treatment, the total follow-up time was 
68 787·15 person-years (median 4·96, IQR 4·68–5·28), 
with a mortality rate of 36·36 (95% CI 34·96–37·81) per 
1000 person-years (appendix p 13).
Compared with the São Paulo state population—
matched by age, sex, and calendar years—the SMR over 
the 5 years of follow-up was 6·47 (95% CI 6·22–6·73) and 
8·06 (7·56–8·58) for patients with vulnerable conditions. 
The SMR was highest for those aged 35–45 years and 
during the first year of follow-up (table 2). Among those 
who survived the first year, the overall SMR was 3·93 
(95% CI 3·71–4·17) and was 5·25 (4·80–5·73) for patients 
with vulnerable conditions (table 2).
We found an increase in the proportion of deaths 
by baseline characteristics in older (>65 years; 48%), 
illiterate (28%), and immunosuppressed patients (HIV 
positive; 39%; appendix p 14).
After linking TBweb with the mortality database, we 
observed that 320 (18%) of 1773 patients who were lost 
to follow-up or had unevaluated treatment outcomes 
died (appendix p 14). A considerable proportion of these 
patients died soon after loss to follow-up (appendix p 15), 
at a median of 14 months (IQR 5–33). 1055 (9%) of 
12 227 patients with previous treatment success died 
a median of 24 months (IQR 11–39) after successful 
treatment.
The most frequent cause of death was infection 
(1197 [45%] of 2660 deaths), followed by respiratory 
(334 [13%] of deaths), neoplasia (307 [12%] of deaths), 
cardiovascular (280 [11%] of deaths), and external 
causes (174 [7%] of deaths; appendix p 16). After 1 year, 
respiratory, neoplasia, cardiovascular, and external causes 
of death exceeded infection in patients without HIV 
coinfection. In patients younger than 30 years, infection 
(150 [55%] patients) and external causes (49 [18%] 
patients) were responsible for most deaths (appendix p 17). 
Patients with tuberculosis had a different distribution of 
the top ten causes of death compared with the São Paulo 
State population (appendix p 18) and this difference 
was more pronounced among those with vulnerable 
conditions (appendix p 19).
We estimated the crude and age-adjusted and sex-
adjusted associations between exposures and all-cause 
survival (appendix p 20). After fully adjusting for 
confounders, homelessness, alcohol and drug use, or a 
combination of these two factors were consistently 
associated with reduced survival among patients 
with tuberculosis for the different periods analysed 
(table 3). We did not observe an association between 
imprisonment or mental disorder and survival. Diabetes 




any of the 
six exposures* 
(n=10 182)







any of the 
six exposures* 
(n=9347)
Population with at 
least one of the 
six exposures* 
(n=4664)
Overall 6·47 (6·22–6·73) 5·72 (5·43–6·02) 8·06 (7·56–8·58) 3·93 (3·71–4·17) 3·31 (3·06–3·57) 5·25 (4·80–5·73)
Stratified by age, years*
15–25 7·63 (6·28–9·19) 5·28 (4·07–6·75) 7·56 (5·56–10·06) 5·29 (4·07–6·75) 4·77 (3·37–6·55) 6·29 (4·11–9·22)
>25–35 11·73 (10·47–13·09) 8·90 (7·62–10·33) 10·6 (8·95–12·47) 7·31 (6·22–8·52) 6·33 (5·04–7·86) 8·67 (6·88–10·79)
>35–45 13·54 (12·44–14·72) 10·76 (9·58–12·05) 13·69 (12·04–15·50) 8·30 (7·34–9·35) 6·95 (5·84–8·21) 10·39 (8·70–12·32)
>45–55 8·15 (7·49–8·84) 6·79 (6·07–7·58) 8·46 (7·44–9·58) 4·71 (4·15–5·31) 4·01 (3·36–4·74) 5·83 (4·85–6·96)
>55–65 5·38 (4·88–5·92) 4·68 (4·12–5·28) 5·39 (4·58–6·30) 3·16 (2·73–3·63) 2·91 (2·41–3·49) 3·63 (2·86–4·55)
>65 3·27 (2·99–3·58) 2·71 (2·43–3·00) 3·09 (2·59–3·67) 1·92 (1·68–2·20) 1·79 (1·52–2·10) 2·33 (1·80–2·98)
Stratified by sex
Female 7·33 (6·76–7·94) 6·59 (5·99–7·24) 10·31 (8·81–11·99) 4·25 (3·76–4·78) 3·67 (3·16–4·23) 6·62 (5·27–8·20)
Male 6·23 (5·95–6·52) 5·42 (5·10–5·76) 7·71 (7·19–8·26) 3·85 (3·60–4·11) 3·19 (2·91–3·48) 5·05 (4·58–5·55)
Stratified by follow-up, year
1st 16·54 (15·66–17·45) 15·33 (14·31–16·41) 19·07 (17·43–20·83) ·· ·· ··
2nd 4·45 (3·99–4·94) 3·91 (3·40–4·49) 5·56 (4·68–6·57) ·· ·· ··
3rd 3·82 (3·39–4·28) 3·35 (2·87–3·88) 4·80 (3·98–5·75) ·· ·· ··
4th 3·32 (2·93–3·76) 2·56 (2·14–3·03) 4·95 (4·10–5·91) ·· ·· ··
5th 3·47 (3·04–3·93) 2·76 (2·31–3·28) 5·00 (4·11–6·04) ·· ·· ··
Stratified by previous treatment outcome
Treatment success ·· ·· ·· 3·47 (3·25–3·70) 2·91 (2·67–3·17) 4·71 (4·26–5·20)
Treatment failure ·· ·· ·· 5·23 (3·60–7·34) 5·81 (3·45–9·19) 4·66 (2·61–7·69)
Loss to follow-up or not evaluated ·· ·· ·· 8·75 (7·59–10·03) 7·89 (6·47–9·53) 9·91 (8·06–12·07)
Data are SMRs (95% CI).  SMR=standardised mortality ratio. *The six exposures are incarceration, homelessness, alcohol and drug use, diabetes, and mental disorders.
Table 2: SMRs over 5 years of follow-up of patients newly diagnosed with tuberculosis compared with the São Paulo state population, matched by age, sex, and calendar year
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had a time-dependent effect on survival, with an in-
creasing adjusted HR over the period analysed. A flexible 
parametric survival model confirmed the non-linear risk 
of death (appendix pp 21–22). We observed similar point 
estimates for all associations in the complete case dataset 
(appendix p 23) and considering the starting point for the 
date of treatment outcome (appendix p 24).
Following tuberculosis diagnosis, the hazard rate of 
deaths due to infection reached a plateau and this effect 
was more apparent in those without HIV coinfection 
(appendix p 25).
Among patients with tuberculosis, homelessness, 
alcohol and drug use, or a combination of these factors 
were associated with deaths due to infection (cause-specific 
HR 1·60, 95% CI 1·39–1·85 for the combination), external 
(1·66, 1·18–2·33 for the combination), and ill-defined 
causes (2·06, 1·31–3·25 for the combination; figure; 
appendix p 26). Mental disorders were associated with 
respiratory (1·76, 1·09–2·85) and ill-defined causes (2·39, 
1·00–5·67) of death. Diabetes (1·70, 1·23–2·35) and the 
combination of homelessness and alcohol and drug use 
(1·43, 1·06–1·95) were associated with cardiovascular 
deaths. A similar association was observed among those 
without immunosuppression (appendix pp 27–28).
For cause-specific fully adjusted HRs for exposures 
among those who survived the first year we observed an 
association between the combination of homelessness 
and alcohol and drug use and all causes of death, except 
neoplasia, and diabetes with cardiovascular causes 
(appendix pp 29–30). After 1 year of follow-up, prison 
incarceration was associated with external causes of 
death (cause-specific HR 1·64, 95% CI 0·98–2·74).
Cumulative incidence curves for the first regrouping of 
causes of death are shown in the appendix (p 31). The 
5-year survival (n=15 342) 1-year survival (n=15 342) Among those alive at 1 year (n=14 011)
Patients Deaths Adjusted HR 
(95% CI)*
p value Patients Deaths Adjusted HR 
(95% CI)*




Incarcerated ·· ·· ·· 0·189 ·· ·· ·· 0·388 ·· ·· ·· 0·261
No 13 736 2376 (17%) 1 (ref) ·· 13 736 1274 (9%) 1 (ref) ·· 12 462 1102 (9%) 1 (ref) ··
Yes 1 606 125 (8%) 0·88 (0·73–1·07) ·· 1606 57 (4%) 0·88 (0·67–1·17) ·· 1549 68 (4%) 0·86 (0·66–1·12) ··
Homelessness ·· ·· ·· <0·0001 ·· ·· ·· 0·0009 ·· ·· ·· 0·0081
No 14 966 2382 (16%) 1 (ref) ·· 14 966 1263 (8%) 1 (ref) ·· 13 703 1119 (8%) 1 (ref) ··
Yes 376 119 (32%) 1·51 (1·25–1·83) ·· 376 68 (18%) 1·54 (1·19–1·98) ·· 308 51 (17%) 1·48 (1·11–1·97) ··
Health behaviours
Alcohol use ·· ·· ·· <0·0001 ·· ·· ·· 0·0006 ·· ·· ·· <0·0001
No 13 311 1988 (15%) 1 (ref) ·· 13 311 1070 (8%) 1 (ref) ·· 12 241 918 (8%) 1 (ref) ··
Yes 2031 513 (25%) 1·36 (1·22–1·51) ·· 2031 261 (13%) 1·30 (1·12–1·52) ·· 1770 252 (14%) 1·42 (1·22–1·66) ··
Drug use ·· ·· ·· 0·030 ·· ·· ·· 0·302 ·· ·· ·· 0·026
No 14 324 2318 (16%) 1 (ref) ·· 14 324 1236 (9%) 1 (ref) ·· 13 088 1082 (8%) 1 (ref) ··
Yes 1018 183 (18%) 1·20 (1·02–1·41) ·· 1018 95 (9%) 1·13 (0·90–1·41) ·· 923 88 (10%) 1·31 (1·03–1·65) ··
Comorbidities
Diabetes mellitus† ·· ·· ·· 0·067 ·· ·· ·· 0·084 ·· ·· ·· 0·011
No 14 472 2279 (16%) 1 (ref) ·· 14 472 1233 (9%) 1 (ref) ·· 13 239 1046 (8%) 1 (ref) ··
Yes 870 222 (25%) 0·83 (0·67–1·02) ·· 870 98 (11%) 0·83 (0·67–1·03) ·· 772 124 (16%) 1·28 (1·06–1·56) ··
Mental disorder ·· ·· ·· 0·439 ·· ·· ·· 0·147 ·· ·· ·· 0·649
No 15 011 2421 (16%) 1 (ref) ·· 15 011 1283 (9%) 1 (ref) ·· 13 728 1138 (8%) 1 (ref) ··
Yes 331 80 (24%) 1·09 (0·87–1·38) ·· 331 48 (15%) 1·25 (0·93–1·68) ·· 283 32 (11%) 0·92 (0·64–1·32) ··
Combined
Alcohol or drug use 
or homelessness
·· ·· ·· <0·0001 ·· <0·0001 ·· <0·0001 ·· ·· ·· <0·0001
No 12 558 1852 (15%) 1 (ref) ·· 12 558 998 (8%) 1 (ref) ·· 11 560 854 (7%) 1 (ref) ··
Yes 2784 649 (23%) 1·45 (1·32–1·60) ·· 2784 333 (12%) 1·37 (1·20–1·57) ·· 2451 316 (13%) 1·55 (1·35–1·78) ··
Alcohol and drug 
use and 
homelessness
·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
One factor 2199 500 (23%) 1·38 (1·25–1·54) ·· 2199 253 (12%) 1·31 (1·13–1·51) ·· 1946 247 (13%) 1·47 (1·27–1·71) ··
Two factors 529 132 (25%) 1·73 (1·44–2·08) ·· 529 69 (13%) 1·57 (1·22–2·02) ·· 460 63 (14%) 1·97 (1·51–2·57) ··
Three factors 56 17 (30%) 2·11 (1·30–3·42) ·· 56 11 (20%) 2·36 (1·29–4·30) ·· 45 6 (13%) 1·75 (0·77–3·93) ··
HR=hazard ratio. *Fully adjusted models in ten multiple imputed datasets. †Time-varying effect of diabetes mellitus interacting with survival time HR for the interaction term 1·15 (95% CI 1·05–1·25); p=0·0015.
Table 3: Association between social vulnerability, health behaviours, and comorbidities and 5-year survival of patients newly diagnosed with tuberculosis
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homelessness and alcohol and drug use combination 
was associated with all causes of death (HR 1·80, 
95% CI 1·37–2·36 for external or ill-defined causes), 
except respiratory causes (not pneumonia), over 5 years 
(appendix pp 32–35) and after the first year (appendix pp 
36–37). The combination of homelessness and alcohol 
and drug use had the highest point estimate for external 
or ill-defined causes (cause-specific HR 1·89, 95% CI 
1·36–2·62), followed by tuberculosis (1·82, 1·06–3·12) 
after 1 year.
Cumulative incidence curves for deaths attributed to 
tuberculosis are shown in the appendix (p 38). 531 (20%) 
of 2660 total patients who died had tuberculosis as the 
underlying cause of death and 366 (14%) had tuberculosis 
mentioned in other lines of their death certificate. When 
we analysed deaths during the first year, 462 (31%) of 
1490 patients who died had tuberculosis as the underlying 
cause of death and 294 (20%) had tuberculosis mentioned 
in other lines of their death certificate; these proportions 
were 69 (6%) of 1170 and 72 (6%) of 1170, respectively, 
among those who survived after the first year. The 
homelessness and alcohol and drug use combination was 
associated with death with any mention of tuberculosis 
over 5 years (appendix pp 39–40) and after 1 year (cause-
specific HR 1·83, 95% CI 1·26–2·66; appendix pp 41–42).
Discussion
In this population-based study in São Paulo state, Brazil, 
we observed that 2660 (17%) of 15 501 patients with 
tuberculosis died within 5 years after tuberculosis 
diagnosis. Mortality among patients with tuberculosis 
was six-times higher than the source population, and 
four-times higher for those who survived the first year. 
Infection was responsible for most deaths. Home-
lessness, alcohol and drug use, and diabetes were 
associated with lower survival among patients 
with tuberculosis. These vulnerable conditions were 
associated with cause-specific mortality such as death 
from tuberculosis, from external or ill-defined causes, 
and cardiovascular causes.
In 2017, as estimated by WHO, there were around 









0·25 0·50 1·0 2·0 4·0 0·25 0·50 1·0 2·0 4·0 0·25 0·50 1·0 2·0 4·0
0·25 0·50 1·0 2·0 4·0
Cause−specific HR
0·25 0·50 1·0 2·0 4·0
Cause−specific HR











Cardiovascular External causes Ill-defined
Figure: Fully adjusted cause-specific HRs for 5-year cause-specific mortality in patients newly diagnosed with tuberculosis
Boxes show adjusted cause-specific HRs and error bars show 95% CIs. Arrowheads represents the direction of the CI value, truncated at the horizontal axis limit. HR=hazard ratio.
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treatable disease; therefore, deaths and tuberculosis-
associated sequelae should be avoidable.1,13 Accurate 
estimation of the tuberculosis attributable burden is 
fundamental to guide public health programmes and 
prioritise global policy decisions.1,25,26 A strength of this 
study is evaluation of the long-term survival of patients 
with tuberculosis in a high-burden country, with 
application of competing risk analysis to study cause-
specific mortality among patients with tuberculosis, and 
using data from death certificates from an established 
vital registration system.
We observed that patients with tuberculosis died at a 
higher rate than the source population over 5 years of 
follow-up, similar to findings previously reported in 
India (SMR 6·1; for 2000–03).10 When considering 
those who survived the first year, we observed a SMR 
comparable to that reported in post-treatment cohorts in 
Israel (3·7; for 2000–10),7 and Vietnam (4·0; for 2010–13).11 
Although this study is restricted by not using individual 
data to build a cohort without tuberculosis and not 
disentangling excess mortality from tuberculosis itself or 
vulnerable conditions, we observed that patients with 
tuberculosis with vulnerable conditions had even higher 
excess mortality (SMR 8·1 over 5 years, and 5·3 for those 
who survived the first year), compared with the source 
population. The highest SMRs were for those aged 
20–40 years,10,12 showing how tuberculosis affects a 
working age population, and indicating the need to better 
evaluate the catastrophic costs associated with 
tuberculosis after treatment.27
The main reason for several countries, including 
Brazil, not achieving the WHO treatment outcome goal 
is loss to follow-up.1,14 After linkage with the mortality 
database, we observed that patients who had initially 
been declared lost to follow-up in the treatment database 
actually died soon after. This result reinforces the 
recommendation that national programmes should 
focus on high-risk groups to decrease their risk of loss 
to follow-up. Additionally, our findings reiterate the 
importance of record linkage and monitoring of post-
tuberculosis treatment mortality, to provide more 
accurate data for national programmes and burden 
estimation.1,25,26
The combination of homelessness and alcohol and drug 
use among patients with tuberculosis was associated with 
every cause-specific mortality we investigated except 
neoplasia. Previous studies showed that these conditions 
were associated with all-cause mortality,3 particularly 
alcohol consumption, in high-income countries12,28 and 
low-income and middle-income countries.10 Although 
not estimated by a quantitative measure of association 
(eg, cause-specific HR), studies done in Israel7 and 
Denmark12 with death certificate data, together with the 
study from Vietnam,11 which used verbal autopsy, reported 
a higher proportion of deaths probably associated with 
alcohol and drug use among patients with tuberculosis 
compared with the source population. We observed that, 
among patients with tuberculosis, lower acute respiratory 
infections and chronic respiratory diseases were the top 
causes of death, which is compatible with evidence 
showing post-tuberculosis lung sequelae.13 120 successfully 
treated patients with tuberculosis were evaluated for lung 
function in Brazil in 2013–14 and alcohol use was one of 
the factors associated with worse lung function,29 
highlighting that this population might benefit from 
already well known and simple interventions, such as 
pneumococcal and influenza vaccines, and a programme 
to reduce alcohol consumption.
Diabetes is a key comorbidity in the tuberculosis 
epidemic,1 and tuberculosis was ranked as the first cause 
of death among patients with tuberculosis who had 
diabetes. We observed that diabetes was non-linearly 
associated with all-cause mortality, starting from a 
protective association to a smoothed increase in risk over 
time. This pattern disappeared for cause-specific 
mortality, when diabetes was consistently associated with 
cardiovascular deaths. Our results are in accordance with 
a study in Mexico (from 1995–2010), which observed 
worse intermediate outcomes during treatment, but no 
increased risk of tuberculosis-related mortality for 
patients with diabetes.30 We had no information about 
diabetes severity or glycaemic control for patients with 
tuberculosis, factors that could help explain the complex 
association between diabetes, treatment outcomes, and 
all-cause mortality.
Imprisonment is a particularly vulnerable condition. 
We observed that imprisonment was not associated with 
worse all-cause survival, but imprecisely associated with 
external causes of death after the first year of follow-up. 
The presence of other vulnerable factors (eg, tuberculosis 
and HIV coinfection and alcohol use) could explain part 
of this finding,31 associated with substantial collaborative 
efforts of the São Paulo State Tuberculosis Program to 
improve treatment outcomes for tuberculosis cases that 
occur in prisons.15
This study has limitations that must be acknowledged. 
First, we used a population-based cohort, and because 
notification is compulsory and needed for medication 
delivery in Brazil, it is unlikely we have missed a relevant 
number of cases that started treatment (not considering 
cases diagnosed after death). However, routine databases 
have intrinsic limitations—not all patients were tested 
for HIV or anti-tuberculosis drug resistance. However, 
HIV testing was relatively high1 and we allowed a 
baseline hazard for each HIV status in the Cox models. 
Regarding MDR tuberculosis, Brazil and São Paulo have 
historically low proportions of MDR disease among new 
cases (<1% in 2010);17 this proportion was maintained 
after the ruling out of rapid diagnostic tests,1 so we did 
not expect much bias from possible misclassification. 
Second, the sample size was pragmatically chosen to be 
feasible for probabilistic linkage with manual review. 
This factor might have affected our power to detect some 
associations for cause-specific mortality. Additionally, 
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the performance of the probabilistic linkage was 
excellent, but estimated with the mortality data entered 
into TBweb. Thus, the linkage procedure could have 
lower sensitivity than estimated. We guaranteed high 
specificity by manually reviewing all pairs selected in 
the probabalistic record linkage. Third, to ascertain a 
single cause of death is arbitrary and we overcame this 
by sensitivity analyses. Fourth, point estimates 
could be overestimated because of positive residual 
confounding—we had no data about smoking or 
nutritional status. Additionally, some of our exposures 
had no quantitative or cumulative information, such as 
alcohol consumption. Finally, we excluded patients who 
had been retreated for tuberculosis, who are associated 
with vulnerable conditions and lower survival,1,3 thereby 
limiting our generalisability to all patients with 
tuberculosis and underestimating the total disease 
burden.
Our study provides an extensive epidemiological 
analysis of long-term survival and cause-specific 
mortality of tuberculosis in a high-burden country, 
showing that this disease makes a notable contribution 
to excess mortality and its association with vulnerable 
conditions. Policy makers, society stakeholders, commu-
nity members, and health professionals should con-
centrate efforts to tackle tuberculosis and its association 
with various vulnerable conditions.
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